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Abstract 
Background: Intermittent mass screening and treatment (iMSaT) is currently being evaluated as a possible addi-
tional tool for malaria control and prevention in western Kenya. The literature identifying success and/or barriers to 
drug trial compliance and acceptability on malaria treatment and control interventions is considerable, especially as it 
relates to specific target groups, such as school-aged children and pregnant women, but there is a lack of such stud-
ies for mass screening and treatment and mass drug administration in the general population.
Methods: A qualitative study was conducted to explore community perceptions of the iMSaT intervention, and 
specifically of testing and treatment in the absence of symptoms, before and after implementation in order to identify 
aspects of iMSaT that should be improved in future rounds. Two rounds of qualitative data collection were completed 
in six randomly selected study communities: a total of 36 focus group discussions (FGDs) with men, women, and 
opinion leaders, and 12 individual or small group interviews with community health workers. All interviews were con-
ducted in the local dialect Dholuo, digitally recorded, and transcribed into English. English transcripts were imported 
into the qualitative software programme NVivo8 for content analysis.
Results: There were mixed opinions of the intervention. In the pre-implementation round, respondents were 
generally positive and willing to participate in the upcoming study. However, there were concerns about testing in 
the absence of symptoms including fear of covert HIV testing and issues around blood sampling. There were fewer 
concerns about treatment, mostly because of the simpler dosing regimen of the study drug (dihydroartemisinin–
piperaquine) compared to the current first-line treatment (artemether–lumefantrine). After the first implementation 
round, there was a clear shift in perceptions with less common concerns overall, although some of the same issues 
around testing and general misconceptions about research remained.
Conclusions: Although iMSaT was generally accepted throughout the community, proper sensitization activities—
and arguably, a more long-term approach to community engagement—are necessary for dispelling fears, clarifying 
misconceptions, and educating communities on the consequences of asymptomatic malaria.
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Background
In recent years, much progress has been made in the fight 
against malaria, resulting in substantial global reductions 
in mortality and incidence rates—a result of increased 
funding and commitment to prevention and treatment 
strategies [1, 2]. However, malaria remains a disease 
of public health significance around the world, as there 
were an estimated 214 million malaria cases and 438,000 
deaths attributed to it in 2015 [1]. Further interventions 
are necessary to sustain the progress that has been made 
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and to accelerate the reduction in disease burden, transi-
tioning from strategies of control to those of elimination.
There is increasing recognition of the complexities that 
come with implementing community wide health inter-
ventions like intermittent mass screening and treatment 
(iMSaT), mass drug administration (MDA), insecticide-
treated bed net (ITN) distribution, indoor residual spray-
ing (IRS), and intermittent preventive treatment (IPT), 
which are aimed at malaria control and prevention [3–7]. 
Okello and colleagues [4] comment on the results from 
past studies on the acceptability of such interventions 
which reveal a variety of influencing factors including 
perceptions of disease burden and aetiology; perceptions 
of the safety, effectiveness, and benefits of the treatment 
or intervention; individual, social and cultural factors 
within the community; and structural and system fac-
tors. This body of literature covers a range of interven-
tions and tools including IPT [6–9], iMSaT [10], RDTs 
[11, 12], IRS [13], and community case management of 
malaria and seasonal malaria chemoprevention [14]. The 
literature on the acceptability of iMSaT in the general 
population is minimal but includes a recent paper from 
a study conducted in Zambia [3]. Researchers discuss 
various testing-related fears and misconceptions as well 
as inadequate information about the study as primary 
reasons for refusals. They underscore the importance of 
increased community sensitization and improved com-
munication to counter misinformation and to increase 
acceptance and effectiveness of the intervention. It is 
essential to understand community perceptions both 
before the intervention in order to plan its delivery and 
ensure optimum uptake [15–17] as well as after the com-
pletion of treatment rounds so as to improve effective-
ness and strategies for scale-up [3].
The Centers for Disease Control and Prevention (CDC) 
and the Kenya Medical Research Institute (KEMRI) 
have been collaborating on malaria research and public 
health programmes in western Kenya for over 35  years. 
Researchers are currently evaluating iMSaT as a pos-
sible additional tool for malaria control and prevention 
in Siaya County, western Kenya. The iMSaT study will 
assess the impact of repeated rounds of mass screening 
and treatment on malaria transmission, morbidity and 
mortality over a 2–3  year period. In this strategy, every 
individual within a community is screened for malaria 
with a rapid diagnostic test (RDT) at the household level, 
regardless of the presence or absence of symptoms, and 
persons found to be positive are treated with dihydroar-
temisinin-piperaquine (Duo-Cotecxin®, Holley-Cotec 
Pharmaceuticals Co. Ltd., Beijing), taken once a day for a 
total of 3 days. Nested within the iMSaT study is a quali-
tative data collection component to document commu-
nity perceptions on the iMSaT intervention (including 
testing and treating) before and after the first implemen-
tation round. This paper will present the findings from 
this latter component.
Methods
Study site
The study was conducted in Siaya County in Nyanza 
Province in western Kenya—an area of high malaria 
transmission throughout the year, where the prevalence 
of malaria parasitaemia is approximately 40 % in the gen-
eral population (unpublished data, KEMRI-CDC). Resi-
dents are primarily from the Luo ethnic group, earning 
a living through subsistence farming, fishing, and small 
businesses [18]. In 2001, KEMRI-CDC launched a health 
and demographic surveillance system (HDSS) in Nyanza 
Province. The KEMRI-CDC HDSS conducts malariomet-
ric monitoring through a variety of methods, including 
hospital and outpatient surveillance, annual parasitae-
mia and anaemia surveys, monthly entomological sur-
veys, and entomological insecticide resistance testing, 
among others. The communities living in the study area 
are, therefore, familiar with KEMRI-CDC’s work, often 
participating in clinical trials and other epidemiological 
studies over the past few decades. Malaria transmission 
in the area is high and perennial, with peak transmis-
sion in May–July and October–November. Plasmodium 
falciparum is the dominant malaria parasite species. In 
July 2006, artemether–lumefantrine (Coartem®, Novartis 
Pharmaceuticals Corporation, Basel) was introduced as 
first-line treatment for uncomplicated malaria and was 
provided in government and mission health facilities; in 
2012, the Kenya Ministry of Health adopted a universal 
policy requiring diagnostic confirmation of all individuals 
with reported or documented fever where this is possible 
before they are given treatment for malaria in facilities 
where this is possible [19]. Siaya County also bears one of 
the highest HIV prevalence rates among adults (17.8 %) 
in the country, following Homa Bay (27.1 %), and Kisumu 
(18.7  %). These most recent figures from 2012 compare 
with a national average prevalence of 5.6 % among adults 
aged 15–49 years [20].
Qualitative study design
The overall aim of the iMSaT qualitative data collection 
component was to explore community perceptions of the 
screening and treatment intervention before and after the 
first implementation round in order to identify aspects 
of the iMSaT activities that might be improved in future 
rounds or if iMSaT becomes policy. The pre-implemen-
tation round was intended to serve as a reference point 
and to provide sociocultural information that might be 
relevant for the initial round of iMSaT activities. The 
purpose of the post-implementation data was to provide 
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community feedback on the first round of iMSaT to iden-
tify possible areas where iMSaT procedures should be 
strengthened or revised or whether additional commu-
nity sensitization was needed. Topics included general 
information about community knowledge of malaria, 
malaria care-seeking and prevention behaviours, and 
preferences of anti-malarial drugs, but focused primar-
ily on perceptions of and experiences with malaria test-
ing and treatment in the absence of symptoms in order to 
anticipate reasons for refusal to participate in the study.
Selection of study communities
Six study communities were randomly selected in the 
KEMRI-CDC HDSS area (two each from Karemo, Gem, 
and Asembo which were all administrative districts at the 
time). These villages formed part of the total 41 interven-
tion communities of the wider iMSaT study. Qualitative 
data were collected in the same six communities twice: 
once in July 2013 (pre-implementation), and again in 
November 2013 (post-implementation). The timing of 
these data collection rounds corresponds to the periods 
of peak malaria transmission in Kenya (May–Jul; Oct–
Nov). This paper presents only the data before and after 
the first round of iMSaT in order to capture initial per-
ceptions and describe their role in informing the first 
rounds of iMSaT delivery. Because the iMSaT interven-
tion involves multiple rounds, it is reasonable to expect 
that community perceptions after the first round might 
evolve after several repeated rounds; for this reason, an 
additional set of qualitative data was collected. Analysis is 
underway and will be reported separately.
Data collection methods and participant recruitment
Qualitative data were collected by an eleven-member 
field team consisting of a field supervisor, research 
assistant, and nine interviewers. Additionally, the co-
investigator for the qualitative component conducted 
the interviewer training and oversaw data collection for 
the pre-implementation round. Data collection methods 
included focus group discussions (FGDs) with commu-
nity members, and small group or individual interviews 
with community health workers (CHWs) in each study 
community, depending on the number of CHWs avail-
able. All interviews were conducted in the local dialect 
Dholuo, digitally recorded, and transcribed into English 
within 48  h of completion. A total of 36 FGDs and 12 
interviews with CHWs were conducted.
FGDs were used to explore community experiences 
and perceptions of malaria testing and treatment in the 
absence of symptoms. Other main topics included com-
munity knowledge about malaria etiology, prevention, and 
treatment, malaria care-seeking and prevention behav-
iours, and knowledge and opinions of anti-malarial drugs.
Three FGDs were conducted in each of six study com-
munities per data collection round: one with community 
opinion leaders, one with adult males, and one with adult 
females. Each FGD consisted of 5–12 participants. Par-
ticipants for the opinion leader FGDs were purposively 
selected in consultation with community leaders and some-
times included both men and women. Participants for the 
male and female FGDs were randomly selected from a list 
of village members from the HDSS, which was then pro-
vided to village leaders in advance of interviews. Village 
leaders visited consecutive names on the list until 12 com-
munity members agreed to participate in the FGD. Occa-
sionally, a community member from the original list of 12 
did not turn up for the FGD (or the village leader failed 
to inform them in advance); in this case, the village leader 
appointed another community member to fill his/her place.
The CHW interviews explored community percep-
tions of malaria testing and treatment in the absence of 
symptoms as well as malaria caseload and management, 
and the CHWs’ role in the iMSaT activities. All CHWs 
in the study community were invited to take part in the 
CHW interviews. Although the original study design 
included FGDs with CHWs, the number of CHWs resid-
ing in the study communities ranged from one to five. 
As a result, the format of the CHW interviews depended 
on the number of available CHWs. Small group CHW 
interviews were conducted in all six communities dur-
ing the pre-implementation round and in five of six study 
communities during post-implementation; an individual 
CHW interview was conducted in the remaining com-
munity where only one CHW was available (yielding 
a total of 12 CHW interviews from both rounds). Total 
numbers of participants by FGD/interview type in each 
round are listed in Table 1.
Interview procedures
Before the start of qualitative study, an initial round of sen-
sitization meetings had already been conducted among 
communities in the study area in order to introduce the 
iMSaT intervention and explain the purpose of treating 
asymptomatic malaria. During the first round of inter-
views (pre-implementation), the iMSaT study was again 
introduced, and participants were shown a sample RDT 
kit (Carestart™ Malaria HRP-2) as well as a sample of the 
Table 1 Total number of  participants by  interview type 
and data collection round
FGD/Interview type Pre-iMSaT round Post-iMSaT round
Opinion leader 52 52
Male 41 51
Female 52 49
CHW 17 20
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study drug (Duo-Cotecxin®). This was to facilitate dis-
cussion and to assess their willingness to undergo testing 
and treatment as part of the upcoming intervention. The 
discussion focused on perceptions of Duo-Cotecxin as it 
was the study drug used in the first two rounds of iMSaT; 
however, a different brand, Eurartesim® (Sigma-Tau 
Pharmaceuticals Inc., Pomezia), was used in subsequent 
rounds. The moderator explained that the drug was to 
be taken once a day for a total of 3 days, unlike the famil-
iar malaria drug available in the community (Coartem®), 
which requires multiple doses throughout the day. Par-
ticipants were allowed to touch the RDT kit and the drug 
packaging, and any questions concerning the drug were 
addressed. They were also informed that the drug would 
offer them protection from malaria for a period of 6 weeks 
unlike Coartem, which would offer a protection period of 
2  weeks. Respondents were asked their opinion of being 
tested and/or treated in the absence of symptoms.
Data management and analysis
Digitally recorded interviews were transcribed directly 
into English from Dholuo. Upon completion, all tran-
scripts were reviewed for accuracy by FA, a native 
Dholuo speaker. No personal identifiers were used in 
the transcripts. The transcripts were then imported into 
NVivo8 for coding and content analysis. During the cod-
ing process, each transcript was read twice, line-by-line, 
and thematic codes were applied to relevant portions of 
text. The initial coding template was developed by DRA 
and KS, and subsequently revised by KS. KS had primary 
responsibility for coding and content analysis.
Ethical approval and consent procedures
Ethical approval for the study was obtained from KEM-
RI’s Ethical Review Committee (reference #SSC 2380) 
and CDC’s Institutional Review Board (reference #6374). 
Overall community consent was obtained through meet-
ings with community leaders in which a series of pres-
entations were made to explain the purpose of the study. 
Each community was visited prior to the start of data 
collection in order to meet with village elders and to col-
lect community descriptors. Written consent (signed or 
thumb print) was obtained from each FGD and CHW 
participant prior to beginning the interview process. 
During both community sensitization and the FGD/
interview consent process, community members were 
reminded of their right to opt out of the study without 
any consequence to themselves or their families.
Results
Several overarching themes emerged from the data: gen-
eral perceptions of research and of KEMRI-CDC; percep-
tions and experiences of RDTs and testing in the absence 
of symptoms; perceived purpose and benefit of iMSaT; 
perceptions and experiences of malaria treatment in the 
absence of symptoms; concerns about drug availabil-
ity and affordability, issues around drug adherence, and 
community suggestions of further sensitization for future 
iMSaT rounds.
Pre-implementation results
General perceptions of research and of KEMRI‑CDC
Although not the primary focus of this study, participants 
often discussed their perception of research as a whole and 
their previous experiences with other studies. These com-
ments were often probed with follow-up questions when 
the content seemed relevant to iMSaT. As noted above, the 
iMSaT study is being conducted in a part of western Kenya 
where there is a long and well-established research col-
laboration between KEMRI and CDC. Participants often 
invoked this research collaboration in their responses, 
sometimes referring to it as “KEMRI-CDC”, “CDC-KEMRI”, 
or other times simply as “KEMRI” or “CDC.” Participants’ 
views on the role of these research institutions varied. 
While some expressed a positive view of KEMRI-CDC and 
were quick to express their appreciation and acceptance of 
research activities (and specifically of the iMSaT study), oth-
ers held more negative views. Some of the latter group sug-
gested that participating in such studies was a waste of time, 
especially when they receive no benefits from participating, 
and linked this with deeper issues of poverty.
Perceptions of RDTs and testing in the absence of symptoms
Respondents were asked about their previous experi-
ences with malaria RDTs and shown a sample testing kit. 
Generally, among the community members who were 
familiar with the RDT, most believed it to be a valuable 
tool and had high expectations of the RDT. They felt that 
it should be able to detect any illness, not just malaria. 
The quotations below refer to participants’ previous 
experiences with RDT testing outside of iMSaT activities.  
M: What is your thought about this RDT testing [for 
malaria]? What do you think about it?
P4: It’s good because it immediately gives out the 
result. That’s one of its advantages that I saw; it gives 
a genuine result. (Male FGD, Asembo)
I think it’s good for our life as it gives results very 
fast whether there’s electricity or not. It will just 
give results of what you want tested. (Female FGD, 
Karemo).
Nevertheless, some who had never been tested with an 
RDT (and even for some who said they had) associated it 
with the HIV testing kit and thus believed the RDT could 
be used for diagnosing both malaria and HIV.  
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M: KEMRI-CDC is planning a study where they 
will visit people in their homesteads to test them for 
malaria even if they do not have any malaria symp-
toms…They will use a type of malaria test that pro-
vides results within 20 min [showing the RDT].
P6: Yes I have seen this, isn’t it used for testing blood?
P3: Yes… it’s used for testing blood…
P4: Isn’t it used for the HIV test?
M: This is only for malaria.
P4: But it looks like the other one. (Male FGD, 
Asembo)
When discussing whether the community would accept 
being tested with an RDT in the upcoming intervention, 
this association of the RDT with HIV testing led some 
community members to suspect that iMSaT staff might 
pretend to test for malaria but actually test for HIV.
Many people will have different opinions especially 
now that we have many HIV cases, they will just say 
that the CDC are pretending but they are testing for 
HIV. (Female FGD, Asembo)
Some will think that they are going to be tested for 
HIV instead of malaria. (Female FGD, Karemo)
Additional concerns about testing centered on the 
issue of giving blood. Many respondents believed that 
too much blood is taken when they participate in clini-
cal studies while others do not like having their finger 
pricked. Others expressed concerns about where the 
blood samples are taken and what they are used for.
You know that when you come in the name of CDC, 
like even some of us whose children were taken by 
CDC, it’s what will make people refuse to partici-
pate in this study. When they hear of blood sam-
ples [being] taken by the CDC group, they will tell 
you that they take too much blood in a full syringe 
like that of a cow, but another person will say that 
a little blood sample is taken for test. That is what 
will make people refuse to participate in the study 
because CDC has a bad reputation. (Female FGD, 
Karemo)
Majority say that they remove lots of blood from 
people and take it somewhere and when a child dies 
they remove the body parts. And as a result people 
get scared about CDC tests but I welcome it because 
I have found help from it. (Female FGD, Asembo)
Perceived purpose and benefit of iMSaT
There was a wide range of understanding regarding the 
purpose and benefit of the iMSaT study. Although the 
concept of asymptomatic malaria infections and the pur-
pose of treating them was explained during initial sensi-
tization meetings, not all of those interviewed recognized 
the value of testing in the absence of malaria symptoms. 
This lack of understanding of asymptomatic malaria led 
to a variety of concerns with both testing and treatment.  
M: In your opinion, how do you think people will feel 
about being tested for malaria with an RDT when 
they do not feel sick?
P1:From my experience I cannot accept to be tested 
when I don’t feel sick…I will wait until I feel sick to 
be tested. (Opinion leader FGD, Asembo)  
M: How do you think people will feel about malaria 
testing when they do not have any symptoms?
P11: On this people’s perceptions will differ, some 
may send them away, those with knowledge who 
have heard of this will accept; therefore people’s per-
ceptions will differ [depending] on how knowledge-
able they are. (Opinion leader FGD, Karemo)
There were some participants, however, who commu-
nicated an awareness of asymptomatic malaria—some 
more clearly than others—and thus recognized more 
readily the value in testing and the purpose of iMSaT. 
Respondents used a variety of phrases and ideas to con-
vey this, such as the concept of “hidden malaria.”
There [are times when] you may feel that you don’t 
have malaria, but you have hidden malaria, there-
fore it is only a test that can show whether you have 
malaria. (Male FGD, Gem)
Someone can live with malaria in their bodies for 
long without knowing it…you think you don’t have 
malaria but it’s already in you, so if you get an 
opportunity to be tested before the malaria symp-
toms show in your body then that will be a good 
opportunity. (Female FGD, Asembo)
Perceptions about malaria treated in the absence 
of symptoms
Compared to concerns about testing in the absence 
of symptoms, there was less concern expressed about 
receiving treatment in the absence of symptoms (once 
tested). Most participants felt that if the test showed 
they were positive for malaria, they would welcome the 
treatment without hesitation. When participants were 
asked about their perception of the study drug Duo-
Cotecxin, some drew on their previous experiences 
with the drug which had been introduced fairly recently 
in some clinics but was not yet widely accessible. The 
majority of responses about Duo-Cotecxin were very 
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positive—mostly due to its perceived high effectiveness 
and simpler dosing regimen as compared with the cur-
rent first-line drug Coartem, which people perceived as 
having lost its “power” and being quite burdensome in 
terms of dosage.
It will be easy for them for now…Coartem and the 
other one, even when taken for days, it’s not effective. 
You take and after 1 week or 2 weeks the malaria is 
still the same. (Opinion leader FGD, Gem)
It is less, so you find that with [Coartem], one gets 
tired with taking it on the way and abandons it 
because you take four tablets and two tablets of Pan-
adol, so it’s not easy…we can encourage them that 
this new drug is easier. (CHW FGD, Asembo)
Drug adherence issues
This discussion of adherence issues emerged as a central 
theme as many participants highlighted the importance 
of completing the full treatment dose although admitted 
they often fail to do so.
Depending on the doctor’s prescription, even when 
feeling well, it is better for a patient to continue tak-
ing or finishing the dosage. That is why it is not pos-
sible to cross a river without passing through water. 
(Opinion leader FGD, Asembo)
I notice some change then I know the medication I 
was given has helped me, but if I don’t notice any 
change it could be that I got lazy and did not finish 
my dose and so the sickness persists, so I just take 
it for granted that the medicine was not effective 
but I am the one who did not complete the dosage. 
(Female FGD, Asembo)
Other reasons for not completing the full dose may 
be due to adverse side effects or wanting to save partial 
doses for when they are ill again.
In our community people like dividing drugs to oth-
ers, somebody takes half and the other people also 
take half dose. Therefore with us we may see that 
the drug is efficient, so if somebody is given drugs, he 
should not share until the dose is over so that habit 
should stop. (Male FGD, Gem)
Other drug‑related concerns
Although the majority of comments surrounding Duo-
Cotecxin were positive, some participants cited ‘fear of 
new things’ as a potential reason for refusal to take the 
drug.  
M: What are the possible reasons for refusals?
P2: Some people fear…such that anytime new things 
are done they are just suspicious. That could be a 
reason for refusal…
P4: …you do not want to change your mind, ideas of 
the past, that’s why people fear
P5: People always fear new things. For some people 
think…‘These new things, do they want to spoil us 
or do they want to make us good’? (Opinion leader 
FGD, Gem).
An additional concern included the potential side effects 
of Duo-Cotecxin, but some participants suggested that 
most community members would comply with the treat-
ment as long as it proved effective and did not cause too 
many side effects.
Participants also wondered about the affordability 
and availability of Duo-Cotecxin based on their previ-
ous experience with the high cost and/or limited drug 
supplies.
The concern they may have is, in case the price can 
go down, that it be locally available, not only at 
[name of local private health center]. It should be 
looked into that the pill becomes available in gov-
ernment hospitals so as to reach the common man. 
(Opinion leader FGD, Karemo)
Community suggestions for iMSaT sensitization activities
Participants were given the opportunity to provide sug-
gestions on what should be done to encourage people to 
participate in the study and to address concerns with test-
ing and treatment. There were many recommendations 
for further sensitization in the communities in order to 
raise awareness and clarify any misconceptions about the 
purpose of the study. While some participants recom-
mended individual counseling during the screening and 
treatment process, others felt that schools and churches 
were the ideal pathways for sharing information.
It depends on someone’s understanding. It is a good 
idea for a person who is doing the testing to talk or 
counsel the person tested for malaria to understand 
the results that show he is positive for malaria but 
still they do not feel sick. (Opinion leader FGD, 
Asembo)
What we think is this: if you want to come for such 
occasions, tell us in advance. Just go to the school…
when it is announced in schools, our children are 
there, and they will then tell us that the malaria 
team will come tomorrow. It is easily done through 
schools. We get information from schools through 
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teachers…the only way to help us is to send mes-
sages through the teacher…or through the church, 
the church on Sunday. (Opinion leader FGD, Gem)
Many participants, especially opinion leaders, believed 
they could also play a role in sensitization by talking with 
community members and sharing the information they 
had learned during the focus groups.
We should encourage each other by involving one or 
two people who have been trained here in [village] to 
educate more people…on what the exercise of mass 
screening is going to entail. Then educating more 
people on what the testing and treatment of malaria 
is all about. (Female FGD, Karemo)
iMSaT sensitization activities
After the completion of the pre-implementation round, 
preliminary results with respect to community sugges-
tions about the need for sensitization were promptly 
shared with the wider iMSaT study team. Prior to imple-
mentation of iMSaT, a round of sensitization activities was 
conducted in study villages targeting the local commu-
nity, opinion leaders, community advisory board (CAB) 
members and CHWs with the aim of addressing study 
concerns. The iMSaT community sensitization team vis-
ited communities to explain how the study fits within the 
agenda of malaria control, introduced thematic areas of 
the study (such as the concept of asymptomatic malaria), 
and discussed basic procedures of participation/selection 
and potential benefits of participation.
Post-implementation round
Overall perceptions of iMSaT
Findings from the qualitative interviews conducted after 
the first round of iMSaT was completed indicate that 
many participants were positive about their overall expe-
riences during the iMSaT household visits and expressed 
their appreciation and willingness to continue with the 
study. Compared to the pre-iMSaT round, the comments 
during post-iMSaT interviews also tended to be more 
positive about KEMRI-CDC.  
M: What are people in this community saying about 
the iMSaT study?
P3: We as those people who were tested are really 
positive
P8: After doing the rounds, people from this commu-
nity appreciated the activities of the iMSaT study
P5: I have heard most people talking positive about 
the IMSAT activities. (Male FGD, Asembo)  
P5: What I hear people saying is that the study has 
really helped people. Even those who didn’t feel sick 
were found with malaria and were given drugs. So 
they appreciated that the study was good
P1: That’s what I heard…people appreciating, and I 
also appreciated it. (Female FGD, Gem)
Some respondents emphasized the importance of the 
study team’s attitude and their exchange with commu-
nity members during household visits. They also high-
lighted the perseverance of the iMSaT teams as they 
returned to households in attempts to screen missed 
groups.
The team worked very well. In fact, there are places 
that they could go to and find children playing out-
side; they would play with those children first to 
calm them down owing to the fact that children are 
scared of being injected/pricked…so they would play 
with those kids, soothe them until they accepted. 
The team worked very well. They were humble and 
walked in peace. (Opinion leader FGD, Asembo)
P4: They were very humble people…aah! Because 
when they came to my house, I was in the garden but 
they took their time…then they tested me, they were 
so humble and patient people.
P2: I loved them because when they came, they could 
teach first what they were to do and only when you 
agreed with their programme is when they would go 
ahead with their testing and treatment. (CHW FGD, 
Karemo, speaking from perspective of study partici-
pants, as they were not part of iMSaT staff)
Experiences with malaria testing
Despite the overall positive comments about the iMSaT 
intervention, concerns about malaria testing remained. 
Many participants still expressed concerns about being 
tested for HIV or had heard rumours that the study 
teams were using malaria as a ploy and actually screening 
for HIV.
The challenge I encountered though small was that 
some people would accept to be tested and oth-
ers wouldn’t. The ones who would refuse would ask 
questions such as ‘this test you’re doing isn’t for 
malaria. You’re lying to us that this test you’re doing 
is for malaria, isn’t it?’ (CHW FGD, Asembo)
Most people in this community fear the tests as 
they always think that every test being conducted 
is for HIV/AIDS…so that’s why you see people run-
ning away because they fear the tests. (Male FGD, 
Karemo)
The issues around blood samples—both fear of giv-
ing blood and confusion as to where the samples were 
taken—again proved to be a main source of unease or 
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dissatisfaction with the process, and oftentimes, a reason 
for refusal to participate in the study.
Some people feared that they have little blood and 
[said] the iMSaT teams were like blood suckers. 
(Female FGD, Gem)
The reason some refused was that most people, even 
those who live in this village, think the KEMRI peo-
ple want to sell their blood. (CHW FGD, Asembo)
During household visits, a finger prick blood sample 
was also collected for preparation of dried blood spots on 
filter paper for assessment of RDT sensitivity. Respond-
ents were particularly confused about this use of filter 
paper in addition to RDTs. It is unclear whether this con-
fusion was due to their own misunderstanding or rather 
to lack of or misinformation given by the iMSaT teams.
After testing me, my blood sample was taken on the 
piece of paper for further screening. It’s not easy for 
me to get the result…this is not easy for us to under-
stand…why the result cannot be given back to me, to 
know what is going on or what was found wrong in 
me. (Male FGD, Asembo)
I can remember being told that it would be taken 
to Atlanta, somewhere in Atlanta but the details 
I’ve forgotten when they said it would be back but 
remember being told it would be taken to Atlanta 
somewhere. (Opinion leader FGD, Karemo)
Experiences with malaria treatment
As anticipated from the pre-implementation round data, 
there were fewer concerns with the treatment component 
of iMSaT, and it was rarely cited as a reason for refusal. 
Many participants expressed their appreciation for the 
treatment and praised the drug’s effectiveness.
It was discovered that some community members 
(from all three districts) had adapted the name of the 
study drug from Duo-Cotecxin to ‘Duokoteko’ meaning 
‘giving energy’ in the local language.
What I saw interesting during the visit was…when a 
person who was screened and found to be malaria 
positive, then Duo-Cotecxin was given, and she got 
healed and felt much better so from that time she 
started calling Duo-Cotecxin drug ‘Duokoteko’ [laugh-
ter]. (CHW FGD, Asembo)
No, we have no problem because it is the same as…
it’s like you are saying some Luo word…‘Duokoteko,’ 
therefore you know it’s like it reduces pain [laugh-
ter]. (Opinion leader FGD, Karemo)
M: And what’s that, ‘Duokoteko’?
P2: There are some people who had malaria…and 
after being tested they were given drugs which made 
them have more energy, that’s why they called it 
‘Duokoteko.’ (CHW FGD, Gem)
There were some participants, however, who believed 
they were being used as “guinea pigs” to test the effective-
ness of Duo-Cotecxin.
It’s like we are being used as guinea pigs to con-
duct study trials with, yet there is nothing that we 
are given. Personally, I am not happy with the study 
activities because we are not gaining anything at all. 
(Male FGD, Karemo)
M: Why did these people refuse to participate in this 
study?
P2: Some people tend to think too far when help 
comes. They think that the CDC people conduct 
research on them when they discover a new drug 
abroad then they come to test it on them to find out 
if it’s effective. So the community members say they 
are not monkeys for research to be conducted on 
them…some people touch on that first then they wait 
to hear from others about the effects. (CHW FGD, 
Asembo)
A common sentiment among those who tested nega-
tive was disappointment they had not received any drugs.
My perception was, I thought after screening I could 
be given some medicine, even if I was not malaria 
positive. I could be given some medicine for emer-
gency in case I fall sick but I did not see [it]. (Male 
FGD, Gem)
Conversely, among those who tested positive and were 
given treatment, it seems that some may have failed to 
finish the full treatment dose.  
M: I would also like to ask you a question, with those 
who took the medicine, how were they…and even 
today?
P2: I would say that most of those people did not fin-
ish the dose. (CHW FGD, Karemo)
P4: I have never been at ease with these new drugs 
because they could have adverse effects that come 
later
M: So, haven’t you taken the drugs you were given?
P4: I haven’t taken them [laughter]. They do have 
adverse effects… it’s something still under trial. 
Those praising the drug may come to cry later. (Male 
FGD, Karemo)
Page 9 of 13Shuford et al. Malar J  (2016) 15:71 
Respondents’ suggestions for further iMSaT rounds
Respondents again encouraged further sensitization as 
well as follow-up visits so as to improve participation 
in subsequent iMSaT rounds. Many respondents com-
mented on the poor sensitization leading up to the study, 
or lack thereof, and believed it to be the main source of 
participant refusals.
This was due to the fact that they were never sensi-
tized…Because all this work was left to the CHWs, 
and no village elders were selected to help in the 
mobilization on the impending visit that was to 
come…So you find that the CHWs come with some 
bag and explain to you what is going to happen, and 
since proper sensitization was not done, some people 
stayed away. (Male FGD, Gem)
I would respond by saying that some people refused 
because of lack of knowledge. Some people would 
refuse because they don’t know the benefits of what 
has been brought to them and its goodness. So my 
advice is before [iMSaT] round 2 begins, mobiliza-
tion and sensitization should be done in the com-
munity. The community members should be able to 
speak for themselves and say that when the CDC 
people brought us treatment for malaria, I felt this 
way after taking the medicine. (CHW FGD, Karemo)
Some noted that with more sensitization, people would 
change their mind about participating in the study after 
seeing positive results from the first round of treatment. 
However, it is important to note that there were refusals 
even among those who received sensitization before the 
study.  
M: For the people who refused…didn’t you carry 
out sensitization?
P2: Sensitization was carried out, but it is diffi-
cult for people to understand things. Some people 
would accept and even sign the consent form. Just 
before you begin your work they say, ‘No, test these 
children and leave me. She is cheating me and 
what I’m seeing here resembles the HIV test kits. 
You want to test for HIV, so just test the children 
and leave me alone.’ So there’s nothing you can 
do- you just test the children and leave her alone. 
(CHW FGD, Gem)
Data from the iMSaT study indicated that refusal 
rates were relatively low, although the number of 
refusals nearly doubled in Round 2 of iMSaT. A 3.3  % 
refusal rate was recorded in the first round of iMSaT 
with a total of 23,199 people sampled and 755 refusals. 
Round 2 and Round 3 of iMSaT (carried out after the 
completion of the qualitative study) resulted in refusal 
rates of 6.0  % (1414/23,699) and 5.6  % (1383/24,676) 
respectively.
Overall, there was little relevant variation across and 
within groups: although female respondents seemed to 
express slightly more concern regarding testing and treat-
ment as compared to their male counterparts, they also 
tended to share more positive statements about the study 
(as compared to males). As might be expected given 
their role within the community, opinion leaders tended 
to be more outspoken and more readily expressed criti-
cism of KEMRI-CDC and research as compared to other 
respondent groups. When CHWs were asked to discuss 
community perceptions and opinions around testing and 
treatment, their comments tended to align with those of 
the community members themselves.
Discussion
Qualitative interviews with community members and 
opinion leaders revealed mixed opinions of iMSaT 
activities. In the pre-implementation round, respond-
ents were generally positive and willing to participate in 
the upcoming iMSaT study. There were, however, some 
concerns related to testing in the absence of symp-
toms including fear of being tested for HIV and issues 
around blood samples. There were fewer concerns about 
the study drug Duo-Cotecxin although these included 
affordability and future availability, but most respond-
ents were positive about the treatment due to its simpler 
dosing regimen. The pre-implementation data were pri-
marily based on hypothetical scenarios or experiences 
outside the iMSaT study (in order to foresee any major 
problems with the intervention); however, these issues 
were largely confirmed in the post-implementation data. 
After the first round of iMSaT, there were less concerns 
and negative views expressed, although some of the same 
issues around testing remained, as these were the most 
common reasons cited for refusal. Although not the pri-
mary focus of this study, community perceptions of the 
KEMRI-CDC research and public health collaboration 
cannot be divorced from the perceptions of the iMSaT 
study. The results suggest that participants’ views and 
acceptance of iMSaT activities were heavily influenced by 
their perception of research as a whole and their previous 
experiences with other studies.
Barriers to acceptability: rumours and misconceptions
The majority of concerns during both pre- and post-
iMSaT centered on fear of covert HIV testing and issues 
related to having samples of blood taken (e.g., confu-
sion surrounding the purpose of the filter paper sam-
ples which were used to test RDT sensitivity). These 
findings are consistent with both Silumbe et  al. [3] and 
Okello et al. [4], which serve as the most directly relevant 
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publications on the subject thus far—providing a set of 
pertinent and overlapping themes.
Rumours about blood (blood-stealing/selling/trading, 
deliberate spread of disease) are quite common and wide-
spread across sub-Saharan Africa [6, 21, 22] and have 
been reported from the region since colonial times [21–
23]. They can affect recruitment of study participants, 
withdrawals/refusals, or adherence issues, but other 
times have no direct impact on research [3, 4, 17, 24]. 
The medical research community has tended to inter-
pret such rumours and misconceptions as expressions 
of ignorance of medical science and the research pro-
cess, or as adherence to traditional beliefs. Findings from 
some studies, however, indicate that rumours should 
not be ignored, given their potential effect on research 
and public health interventions; addressing the rumours 
and engaging with communities could improve relations 
and understanding between researchers or public health 
institutions and study participants [21, 22]. For this rea-
son, and considering the small yet increasing refusal rates 
for iMSaT rounds 2 and 3, a subsequent round of quali-
tative data has been collected to explore the potential 
causes. These data are currently being analysed.
Issues of adherence
Among community members, it was clear that knowl-
edge of malaria was high, as was their awareness of the 
burden and consequences, but there was less awareness 
of the important role of asymptomatic malaria, which 
may have hindered full understanding and acceptance 
of the study. These findings are again consistent with 
Okello’s study [4], which concluded that even with a 
good level of acceptability, a lack of understanding of the 
risk and role of asymptomatic malaria could contribute 
to issues of non-adherence. Although iMSaT communi-
ties were generally positive about Duo-Cotecxin—mostly 
due to its simpler dosing regimen and perceived high effi-
cacy—the results suggest that adherence could become 
problematic even though general acceptability is high. 
While very few iMSaT participants directly mentioned 
their failure to finish the full dose of Duo-Cotecxin 
given by iMSaT teams, their responses regarding gen-
eral adherence behaviour in the community suggest that 
it is very common to stop taking medication due to side 
effects or to perceptions of not being ill, and thus opting 
to save the drugs for later use. The study in the Zambia 
[3] reported similar findings, as did Okello and colleagues 
[4] who concluded (based on what the children’s parents 
suspected) that children either threw away the drugs 
because they feared taking them or because they did not 
believe they had malaria. It is also worth noting that even 
before the start of the iMSaT study, concerns about the 
drug’s affordability, availability, and side effects were very 
common—factors that may also influence access and 
adherence to the drug.
The iMSaT findings highlight the importance of edu-
cating participants about adherence and suggest that 
follow-up visits should continue to be an important and 
necessary component of iMSaT in order to ensure proper 
adherence to the study drug (as some respondents sug-
gested in their recommendations). However, some of the 
same iMSaT participants who admitted to taking partial 
doses of the study drug also emphasized the importance 
of completing treatment as prescribed and conveyed an 
understanding of the dangers of not finishing the full 
dose. This discordance between knowledge and behav-
iour suggests other underlying external factors may be 
at play (outside the iMSaT study) such as access to treat-
ment, cost or availability of drugs, poverty, and other 
structural issues.
Another finding worth highlighting is the study teams’ 
attitude and perseverance which participants remarked 
upon throughout the study. Studies of MDA in the 
neglected tropical diseases (including schistosomia-
sis, soil-transmitted helminths, and lymphatic filariasis) 
have found that the type of drug distributor (e.g., health 
worker, teacher, community-selected) and how and when 
they distribute are often key factors in the acceptabil-
ity and uptake of MDA [25, 26]. This is a programmatic 
element worthy of further attention and research, espe-
cially in conjunction with perceptions of researchers and 
implementers, and should be incorporated into study and 
programme design.
Research perceptions and community engagement
The themes which emerged during the pre-iMSaT round 
of qualitative data collection appear to have anticipated 
the barriers and challenges for household visits and high-
light the need for further, targeted sensitization activi-
ties. The sensitization activities that took place may not 
have been as comprehensive or as effective as expected. 
Given the number of comments on poor sensitization 
(or lack thereof ), and the emphasis participants’ placed 
on issues of blood and HIV, it is likely that some refus-
als or withdrawals were largely due to misinformation or 
misunderstanding of the purpose or intentions of iMSaT 
(as discussed above), or of medical research as a whole—
concerns and beliefs which may have existed for many 
years already. Addressing these will prove challenging; 
fears related to blood are not easily dispelled and may 
actually be linked to deeper issues of power imbalance 
and social distance between researchers and communi-
ties [21]. Dial’s study on MDA in The Gambia [27] cited 
communication as the biggest challenge—specifically 
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the gap between fieldworkers and community members, 
which can perpetuate such fears and rumours around 
blood.
Given the lack of detailed documentation with regard 
to how the iMSaT sensitization activities were conducted, 
it is difficult to know whether or not participants’ con-
cerns were adequately addressed before the first round 
of iMSaT. Regardless, it is also important to recognize 
that these issues may not be merely a question of health 
education, but may require a more long-term, culturally 
appropriate approach to community engagement and 
researcher-community dialogue.
For this purpose, KEMRI-CDC has in place a commu-
nity engagement strategy, which is overseen by a Com-
munity Liaison Officer. Activities include informing the 
community of the objectives of planned and ongoing 
activities, generating community acceptance and sup-
port for the programme, community mobilization for 
informed participation, promoting a positive image of the 
organization, coordinating result disseminations to com-
munity members, coordinating outreach activities, and 
managing rumours and propaganda arising from research 
activities. There is a rich set of literature exploring these 
elements of community engagement and offering insights 
from programmes which have attempted to put them 
into practice in various contexts [28–31]. Although post-
iMSaT responses were overall more positive of KEMRI-
CDC as compared to pre-iMSaT responses, one cannot 
know for certain whether this shift was a result of effec-
tive community engagement and sensitization activities 
or of the intervention itself.
Further recommendations
The qualitative study achieved its original objectives of 
investigating pre- and post-implementation perceptions 
of screening and treatment in the absence of symptoms, 
and the results served to inform delivery of the iMSaT 
intervention. The iMSaT study (and future KEMRI-CDC 
research) would likely benefit from more robust, better 
documented community engagement activities— spe-
cifically tailored to individual studies and to the concerns 
of participating communities. For the remainder of the 
iMSaT intervention rounds, however, a short-term vari-
ation of this approach could be considered in order to 
open communication channels and further clarify mis-
conceptions, thereby improving the acceptability of the 
study and ensuring optimum uptake and adherence to 
the intervention. Although community acceptance of 
iMSaT was generally positive, sensitization still needs 
to be refined and adapted to specific community con-
cerns and misconceptions as outlined in this paper. It is 
imperative to have accurate, consistent, and frequent 
communication from researchers to community mem-
bers and vice versa.
Following suggestions from community members, it is 
clear that future sensitization should continue to incor-
porate village leaders and other trusted group leaders 
(youth or women) who play an important role in commu-
nity buy-in, as discussed in [3, 27]. These activities could 
consist of more interactive meetings in which commu-
nity members can ask questions directly to iMSaT team 
members about the intervention. This would provide an 
opportunity to clarify the purpose of targeting and treat-
ing asymptomatic malaria, to address some participants’ 
expectation of drugs even after a negative test, and to 
reinforce the consequences of not adhering to treat-
ment even when one does not feel sick. Regarding the 
dried blood spots, it should be noted that after round 1 
of iMSaT, these were only collected for a subsample of 
the participants. Nevertheless, given the confusion sur-
rounding the filter paper samples, an option for future 
studies would be to separate this from the main inter-
vention in a more formalized way—perhaps by provid-
ing separate consent forms thereby allowing participants 
to opt out of the dried blood spots but still take part in 
the intervention. Another option would be using the 
RDT test cartridges as a source of blood sample for fur-
ther assays and clearly explaining this to participants. 
Furthermore, communication channels should remain 
open throughout the study; information should continue 
to be disseminated back to the participants after the last 
rounds of iMSaT thereby strengthening partnership and 
fostering trust between researchers and communities.
The findings from this study have also raised some 
important questions regarding the issue of adherence 
and to what extent it is influenced by sensitization efforts. 
The data touched on perspectives from iMSaT partici-
pants who appear to understand the consequences of not 
adhering to treatment and yet choose to not finish their 
dose for various reasons. The community members who 
are continuously sensitized and educated yet fail to fol-
low through illustrate the frustrating complexities of 
community health interventions and drug compliance. 
A more realistic approach may be to accept that there 
will always be a proportion of people who will not ben-
efit from sensitization and may not adhere to treatment. 
Some may argue there is a need for further studies on 
this issue—one which has extensive implications for the 
success and impact of future public health interventions.
Limitations
Most of the pre-implementation data were based on 
hypothetical scenarios of testing and treatment and 
thus may not have identified the full range of factors 
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influencing participation that could occur in later rounds. 
They may overestimate or overemphasize the impor-
tance of negative perceptions which appear to have had 
little effect on actual participation given the low refusal 
rates in the first three rounds of iMSaT. Only six out of a 
total 41 intervention communities were included in the 
qualitative component. However, the number of inter-
views conducted (36 FGDs and 12 CHW interviews) 
comprise a fairly large sample of respondents for a quali-
tative study, and the data suggest that a level of data sat-
uration was achieved as no new themes emerged in the 
final interviews. In addition, despite random selection of 
FGD participants, not all community members on the 
original lists were available at the time of interview. Con-
sequently, village leaders sometimes resorted to conveni-
ence sampling, appointing available community members 
as replacements. Nevertheless, the study benefited from 
triangulation of information from several types of partici-
pants: CHWs, opinion leaders, and male and female com-
munity members of varying age, as well as from all three 
districts in the study area. Although data quality control 
strategies were implemented in an attempt to minimize 
potential bias from the transcription process, there are 
factors which might have influenced transcript content. 
These include translating Dholuo recordings directly into 
English (bypassing written Dholuo), which might have 
resulted in variations in facilitators’ interpretations of 
both local language nuances. Although the small num-
ber of communities included in this study may limit the 
extent to which the results are generalizable to other con-
texts, the findings are consistent with other studies that 
have examined community perceptions of research trials, 
in Kenya and elsewhere.
Conclusion
This qualitative study has explored community per-
spectives of intermittent mass screening and treatment 
for malaria and has identified barriers to acceptability 
and implementation. The findings have implications for 
future mass treatment interventions as well as for wider 
efforts in community engagement. Further sensitization 
activities may help alleviate participants’ concerns by dis-
pelling fears, clarifying misconceptions, and educating 
communities on the role and consequences of asympto-
matic malaria (as shown in other studies). It is necessary, 
however, to approach community engagement and sen-
sitization activities with realistic expectations; there will 
likely be a portion of community members who are not 
very receptive to one-off sensitization activities. A more 
long-term commitment to community engagement and 
communication may improve relations and foster trust 
between such community members and those conduct-
ing the research. Researchers and programmers should 
re-focus their attention on the growing body of informa-
tion on community engagement in practice in order to 
build upon existing models of how research institutions 
and programmes can best integrate their work into study 
communities—thereby facilitating acceptable yet rigor-
ous research which is more likely to have a lasting impact 
on the populations it serves.
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